<DOC>
	<DOCNO>NCT00825955</DOCNO>
	<brief_summary>The purpose study determine Brivanib effective treatment liver cancer patient fail could take Sorafenib</brief_summary>
	<brief_title>Comparison Brivanib Best Supportive Care Placebo Treatment Liver Cancer Those Subjects Who Have Failed Sorafenib Treatment</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Histologic cytologic confirm diagnosis HCC Advanced disease define ( ) disease eligible surgical locoregional therapy ( ii ) disease progressive surgical locoregional therapy Patient fail â‰¥ 14 day Sorafenib treatment Cirrhotic status ChildPugh Class A B score 7 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Subjects life expectancy least 8 week Adequate hematologic , hepatic , renal function woman childbearing potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy Previous concurrent cancer distinct primary site History active cardiac disease Thrombotic embolic event within past 6 month Any hemorrhage/bleeding event &gt; Common Terminology Criteria Adverse Events ( CTCAE ) Grade 3 within 4 week Inability swallow tablet untreated malabsorption syndrome History human immunodeficiency virus ( HIV ) infection Prior use systemic investigational agent HCC ( except Sorafenib )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>